| 1. |
Shiota M, Akamatsu S, Tsukahara S, Nagakawa S, Matsumoto T, Eto M:, Androgen receptor mutations for precision medicine in prostate cancer., Endocr Relat Cancer, 29 (10):R143-R155, 2022, 2022.08. |
| 2. |
Blas L, Shiota M, Eto M:, Current status and future perspective on the management of metastatic castration-sensitive prostate cancer., Cancer Treat Res Commun, 32:100606, 2022, 2022.07. |
| 3. |
Terada N, Aizawa R, Nihei K, Shiota M, Kojima T, Kimura T, Inoue T, Kitamura H, Sugimoto M, Nishiyama H, Mizowaki T, Kamoto T:, Narrative review of local prostate and metastasis-directed radiotherapy in the treatment of metastatic prostate cancer., Jpn J Clin Oncol, 52 (6):633-641, 2022, 2022.05. |
| 4. |
Shiota M, Blas L, Eto M:, Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy., Cancers (Basel) 14 (11):2696, 2022, 2022.05. |
| 5. |
Blas L, Shiota M, Eto M:, Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data., Cancers (Basel) 14 (17):4161, 2022, 2022.08. |
| 6. |
Matsumoto T, Shiota M, Blas L, Eto M:, Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician's Perspective., Cancer Manag Res 14:2389-2397, 2022, 2022.08. |
| 7. |
Masaki Shiota, Naohiro Fujimoto, Eiji Kashiwagi, Masatoshi Eto, The Role of Nuclear Receptors in Prostate Cancer, Cells, 10.3390/cells8060602, Vol.8, No.6, 2019.06, The nuclear receptor (NR) superfamily consists of 48 members that are divided into seven subfamilies. NRs are transcription factors that play an important role in a number of biological processes. The NR superfamily includes androgen receptor, which is a key player in prostate cancer pathogenesis, suggesting the functional roles of other NRs in prostate cancer. The findings on the roles of NRs in prostate cancer thus far have shown that several NRs such as vitamin D receptor, estrogen receptor β, and mineralocorticoid receptor play antioncogenic roles, while other NRs such as peroxisome proliferator-activated receptor γ and estrogen receptor α as well as androgen receptor play oncogenic roles. However, the roles of other NRs in prostate cancer remain controversial or uninvestigated. Further research on the role of NRs in prostate cancer is required and may lead to the development of novel preventions and therapeutics for prostate cancer.. |
| 8. |
Hidetoshi Kuruma, Hiroaki Matsumoto, Masaki Shiota, Andrea Fanjul, David Briere, Gerrit Los, Francois Lamoureux, Christian Thomas, Martin Gleave, Amina Zoubeidi, A NOVEL ANTIANDROGEN PF-05234848 SUPPRESSES CASTRATION-RESISTANT AND MDV-3100-RESISTANT PROSTATE CANCER GROWTH IN VITRO AND IN VIVO, JOURNAL OF UROLOGY, Vol.187, No.4, p.E396, 2012.04. |
| 9. |
クラスタリンによる前立腺癌上皮間葉転換制御
前立腺癌の進展において、上皮間葉転換は、非常に重要な役割を果たしている。そこで、われわれは、前立腺癌の発癌および進展、治療抵抗性に重要な働きをしている分子シャペロンであるクラスタリンの上皮間葉転換における機序と役割について検討した。その結果、TGF-βは、Twist1を介してクラスタリンの発現を誘導することで、上皮間葉転換を促進することが分かった。また、クラスタリンに対するアンチセンスオリゴであるOGX-011(custirsen)は、マウスモデルで前立腺癌転移巣形成を抑制することが分かった。これらより、去勢抵抗性前立腺癌に対して、現在、開発中であるOGX-011(custirsen)は、その転移抑制効果により、前立腺癌治療薬として有望であることが示唆された。(著者抄録). |
| 10. |
＠Matsumoto T, ＠Shiota M:, The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer?, Transl Androl Urol , 9 (5): 2289-2291, 2020, 2020.10. |
| 11. |
Shiota M, Yokomizo A, Fujimoto N, Kuruma H, Naito S:, Castration-resistant prostate cancer: novel therapeutics pre- or post- taxane administration., Curr Cancer Drug Targets, 13 (4): 444-459, 2013, 2013.04. |
| 12. |
Shiota M, Yokomizo A, Naito S:, Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress contributes to treatment resistance in prostate cancer., Endocr Relat Cancer, 2012.06. |
| 13. |
Shiota M, Yokomizo A, Naito S, Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer, Free Radical Biology and Medicine, 2011.10. |
| 14. |
Shiota M, Yokomizo A, Fujimoto N, Naito S, Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer, Current Cancer Drug Targets, 2011.09. |
| 15. |
Shiota M, Yokomizo A, Naito S, Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target, Journal of Molecular Endocrinology, 2011.07. |
